PDS Biotechnology (PDSB) Projected to Post Quarterly Earnings on Wednesday

PDS Biotechnology (NASDAQ:PDSB - Get Free Report) is expected to issue its Q1 2025 quarterly earnings data before the market opens on Wednesday, May 14th. Analysts expect the company to announce earnings of ($0.25) per share for the quarter.

PDS Biotechnology (NASDAQ:PDSB - Get Free Report) last posted its quarterly earnings results on Wednesday, May 14th. The company reported ($0.21) earnings per share for the quarter, topping the consensus estimate of ($0.25) by $0.04. On average, analysts expect PDS Biotechnology to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

PDS Biotechnology Stock Up 5.1%

PDSB stock traded up $0.07 during trading on Wednesday, hitting $1.34. 165,415 shares of the stock traded hands, compared to its average volume of 461,679. PDS Biotechnology has a 1 year low of $0.85 and a 1 year high of $4.42. The firm's 50 day moving average is $1.19 and its two-hundred day moving average is $1.65. The stock has a market cap of $60.97 million, a price-to-earnings ratio of -1.15 and a beta of 1.40. The company has a debt-to-equity ratio of 0.55, a current ratio of 2.84 and a quick ratio of 2.84.

Analyst Upgrades and Downgrades

Separately, HC Wainwright cut their price objective on shares of PDS Biotechnology from $21.00 to $13.00 and set a "buy" rating on the stock in a research report on Thursday, March 27th.

About PDS Biotechnology

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.